<DOC>
	<DOCNO>NCT00348400</DOCNO>
	<brief_summary>Evaluate relative efficacy tolerability Alphagan P compare Trusopt adjunctive therapy</brief_summary>
	<brief_title>Brimonidine Purite 0.15 % Versus Dorzolamide 2 % Used Adjunctive Therapy Latanoprost</brief_title>
	<detailed_description />
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Dorzolamide</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>· Male female &gt; 18 year age Diagnosis openangle glaucoma ocular hypertension IOP &gt; 16 mm Hg eye latanoprost treat baseline evaluation Presently latanoprost monotherapy least 6 week Ability provide inform consent likely complete study visit · Known contraindication allergy brimonidine component Subjects must naive brimonidine 0.2 % brimonidine Purite 0.15 % dorzolamide 2 % Uncontrolled systemic disease Active ocular disease glaucoma ocular hypertension ( e.g . uveitis , ocular infection , severe dry eye ) . Patients chronic mild blepharitis , cataract , agerelated macular degeneration , background diabetic retinopathy may enrol discretion investigator . Required use ocular medication study medication study ( intermittent use artificial tear product allow ) . Corneal abnormality History intraocular surgery within last 3 month Female patient childbearing potential pregnant , lactate , plan pregnancy , use reliable form birth control Visual field loss , opinion investigator , functionally significant , evidence progressive visual field loss within last year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>